Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) inhibitors are crucial for metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF.
• Primary and acquired resistance to EGFR inhibitors limit treatment efficacy in many mCRC patients.
• Molecular alterations like ERBB2 amplification and PI3K/AKT pathway activation drive resistance.

Purpose of the Study:

• To explore the role of negative hyperselection in optimizing patient selection for anti-EGFR therapy in mCRC.
• To investigate the impact of comprehensive molecular profiling on treatment response and survival.
• To highlight the utility of liquid biopsy and emerging therapeutics in overcoming resistance.

Main Methods:

• Comprehensive molecular profiling to identify resistance drivers.
• Analysis of clinical trial data comparing hyperselection with standard selection criteria (RAS/BRAF).
• Utilizing circulating tumor DNA (ctDNA) from liquid biopsies for monitoring and guiding treatment.

Main Results:

• Hyperselected patients demonstrate significantly higher response rates and improved survival compared to standard selection.
• Negative hyperselection effectively excludes tumors with known resistance mechanisms.
• Liquid biopsy enables real-time monitoring of tumor heterogeneity and clonal evolution.

Conclusions:

• Negative hyperselection, guided by comprehensive molecular profiling and ctDNA, represents a precision oncology framework for managing EGFR inhibitor resistance in mCRC.
• This approach enhances patient selection, improves outcomes, and facilitates personalized treatment strategies.
• Emerging therapeutics and advanced monitoring techniques promise further advancements in overcoming resistance and reshaping mCRC care.